文献

J-GLOBAL ID：201702240353632982   整理番号：17A0135507

去勢抵抗性前立腺癌と骨転移のある日本人患者の塩化ラジウム223(BAY88-8223)の単回投与の薬物動態

Pharmacokinetics of single dose radium-223 dichloride (BAY 88-8223) in Japanese patients with castration-resistant prostate cancer and bone metastases

著者 (11件)： Yoshida Keisuke (Department of Radiology, Yokohama City University, Yokohama, Japan) ,  Kaneta Tomohiro (Department of Radiation Oncology/Diagnostic Radiology, Tohoku University Hospital, Sendai, Japan) ,  Takano Shoko (Radiation Oncology, Shonan Kamakura General Hospital, Kamakura, Japan) ,  Sugiura Madoka (Department of Radiology, Yokohama City University, Yokohama, Japan) ,  Kawano Tsuyoshi (Department of Radiology, Yokohama City University, Yokohama, Japan) ,  Hino Ayako (Department of Radiology, Yokohama City University, Yokohama, Japan) ,  Yamamoto Tou (Department of Diagnostic Radiology, Yokohama City University Medical Center, Yokohama, Japan) ,  Shizukuishi Kazuya (Saitama Central Clinic, Saitama, Japan) ,  Kaneko Masato (Clinical Sciences Japan, Bayer Yakuhin Ltd., Osaka, Japan) ,  Zurth Christian (Clinical Sciences, Bayer Pharma AG, Berlin, Germany) ,  Inoue Tomio (Department of Radiology, Yokohama City University, Yokohama, Japan)
資料名： Annals of Nuclear Medicine  (Annals of Nuclear Medicine)
巻： 30  号： 7  ページ： 453-460  発行年： 2016年08月 
JST資料番号： X0838A  ISSN： 0914-7187  CODEN： ANMEEX  資料種別： 逐次刊行物 (A)
記事区分： 原著論文  発行国： ドイツ (DEU)  言語： 英語 (EN)

抄録/ポイント： 目的:この非盲検,非ランダム,第一相試験は,去勢抵抗性前立腺...

シソーラス用語： *前立腺腫瘍 ,...
準シソーラス用語： *去勢抵抗性前立腺癌

ログイン（無料）して見る     続きはJDreamIII（有料）にて  {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=17A0135507&from=J-GLOBAL&jstjournalNo=X0838A") }}

著者キーワード (4件)： Radium-223 ,  Castration-resistant prostate cancer ,  Metastases ,  Pharmacokinetics

分類 (3件)： 腫ようの放射線療法  (GE03034K) ,  泌尿生殖器の腫よう  (GM04000S) ,  薬物の物理化学的性質  (GV01060M)

引用文献 (17件)：

• Turner PG, O’Sullivan J. Radium-223 dichloride for the treatment of metastatic prostate cancer. Expert Opin Pharmacother. 2014;15(14):2105-11.
• 1.5-year post-treatment follow-up of radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase 3 ALSYMPCA Study 9. Clin Adv Hematol Oncol. 2014;12(4 Suppl 11):9-10.
• Anido Herranz U, Fernandez Calvo O, Afonso Afonso FJ, Rodriguez Martinez de Llano S, Lazaro Quintela M, Leon Mateos L et al. Radium-223 dichloride: a new paradigm in the treatment of prostate cancer. Expert Rev Anticancer Ther. 2015; 1-10.
• Hoskin P, Sartor O, O’Sullivan JM, Johannessen DC, Helle SI, Logue J, et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol. 2014;15(12):1397-406.
• Sartor O, Coleman R, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol. 2014;15(7):738-46.

タイトルに関連する用語 (7件)： 去勢抵抗性前立腺癌 ,  骨転移 ,  日本人 ,  患者 ,  塩化ラジウム223 ,  単回投与 ,  薬物動態